Research location

Elizabeth

New Jersey, United States

Published trials110

Site observations113

Linked trials published110

Page1 / 3

Research activity in Elizabeth

New Jersey, United States

CureCurrent currently publishes aggregate city-level research activity for this location: 110 trials and 113 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Elizabeth

110 linked trials · page 1 of 3

Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast CancerNCT07402473 · 2026-03-26 · 1 site observation

DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-AdjustmentNCT07158164 · 2025-08-27 · 1 site observation

Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast CancerNCT06518837 · 2024-10-30 · 1 site observation

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate CancerNCT05946213 · 2023-12-14 · 1 site observation

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerNCT06058377 · 2023-11-27 · 1 site observation

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25NCT05879926 · 2023-10-18 · 1 site observation

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus PembrolizumabNCT05812807 · 2023-06-14 · 1 site observation

Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 TargetedNCT05559164 · 2022-09-19 · 1 site observation

ATATcH Alternating Treatment Plans for Advanced CancerNCT05358548 · 2022-04-28 · 1 site observation

Pilot Trial of Preop Partial Radiation in Breast Cancer PatientsNCT07178665 · 2025-09-02 · 1 site observation

Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam TrialNCT06671912 · 2025-02-19 · 1 site observation

OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast CancerNCT05949021 · 2023-10-07 · 1 site observation

ACTIVE_NOT_RECRUITING

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung StudyNCT05633602 · 2023-03-14 · 1 site observation

ACTIVE_NOT_RECRUITING

CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early StageNCT05333874 · 2022-04-06 · 1 site observation

ACTIVE_NOT_RECRUITING

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance TrialNCT05050084 · 2021-12-06 · 1 site observation

ACTIVE_NOT_RECRUITING

Radiation Therapy Boost Before Surgery for the Treatment of Non-metastatic Breast CancerNCT04871516 · 2021-05-18 · 1 site observation

ACTIVE_NOT_RECRUITING

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT TrialNCT04513717 · 2021-01-21 · 1 site observation

ACTIVE_NOT_RECRUITING

NCI COVID-19 in Cancer Patients, NCCAPS StudyNCT04387656 · 2020-06-05 · 1 site observation

ACTIVE_NOT_RECRUITING

S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung CancerNCT04155034 · 2020-05-04 · 1 site observation

ACTIVE_NOT_RECRUITING

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted TherapyNCT04266249 · 2020-03-13 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) - 1NCT03743051 · 2019-03-05 · 1 site observation

A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast CancerNCT03403712 · 2018-03-16 · 1 site observation

Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02NCT03426345 · 2018-02-16 · 1 site observation

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast CancerNCT02954874 · 2017-01-18 · 1 site observation

ACTIVE_NOT_RECRUITING

Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBCNCT02941926 · 2016-11-30 · 1 site observation

Breast Cancer WEight Loss Study (BWEL Study)NCT02750826 · 2016-09-16 · 1 site observation

ACTIVE_NOT_RECRUITING

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)NCT02465060 · 2015-08-17 · 1 site observation

ACTIVE_NOT_RECRUITING

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast CancerNCT02488967 · 2015-07-26 · 1 site observation

ACTIVE_NOT_RECRUITING

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast CancerNCT02003209 · 2014-02-18 · 1 site observation

Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and MetforminNCT01907854 · 2013-12-02 · 1 site observation

Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.NCT01966107 · 2013-10-16 · 1 site observation

S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast CancerNCT01674140 · 2013-09-12 · 1 site observation

ACTIVE_NOT_RECRUITING

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)NCT01897532 · 2013-07-10 · 1 site observation

TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 DiabetesNCT01829464 · 2013-05-01 · 1 site observation

A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.NCT01783444 · 2013-02-26 · 1 site observation

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose AbnormalitiesNCT01715818 · 2012-12-01 · 1 site observation

Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 DiabetesNCT01606007 · 2012-07-01 · 1 site observation

Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)NCT01601704 · 2012-06-01 · 1 site observation

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular DiseaseNCT01609582 · 2012-06-01 · 1 site observation

Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 DiabetesNCT01481116 · 2012-01-01 · 1 site observation

SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.NCT01475721 · 2011-11-18 · 2 site observations

Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 DiabetesNCT01456195 · 2011-11-01 · 1 site observation

Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes PatientsNCT01422876 · 2011-08-01 · 1 site observation

Study of the Efficacy and Safety of Nebivolol in Younger Patients (18 - 54 Years)NCT01415531 · 2011-08-01 · 1 site observation

Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary DiseaseNCT01313676 · 2011-01-25 · 2 site observations

CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 DiabetesNCT01243424 · 2010-11-11 · 2 site observations

Efficacy and Safety Study to Evaluate Combination Therapy With Nebivolol and Lisinopril vs. Placebo and Monotherapy in Patients With Stage 2 Diastolic HypertensionNCT01218100 · 2010-10-01 · 1 site observation

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor BlockerNCT01137474 · 2010-07-01 · 1 site observation

A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.NCT01128894 · 2010-05-01 · 1 site observation

Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes MedicationsNCT01107886 · 2010-05-01 · 1 site observation

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.